No Picture
Trading Ideas

JPMorgan to Raise Up to $3 Billion for Real Estate Credit Fund

(Bloomberg) — JPMorgan Chase & Co.’s asset-management arm has launched a new fund to take advantage of dislocations in the public and private real estate credit markets, according to a person familiar with the matter.JPMorgan Asset Management is looking to raise $2 billion to $3 billion from institutional investors for the Real Estate Credit Opportunity Fund, according to the person, who asked not to be identified because the information is private.The vehicle will target 10% to 15% net returns investing in bonds and pools of loans tied to commercial real estate, according to documents viewed by Bloomberg. The fund will …read more […]

No Picture
Trading Ideas

Billionaire Anil Agarwal Explores Buyout of India’s Vedanta

(Bloomberg) — Billionaire Anil Agarwal plans to take Indian commodities giant Vedanta Ltd. private as the tycoon continues to simplify his investments.The businessman is proposing a price of 87.5 rupees ($1.16) per share to buy the 49.9% he doesn’t own of the company from minority investors, a 9.9% premium over Monday’s closing price, his holding company said in a statement Tuesday. The announcement confirmed an earlier story by Bloomberg News.Vedanta shares have fallen more than 40% this year, giving the company a market value of about $4.4 billion. Taking the company private is the “next logical step” in its simplification …read more […]

No Picture
Trading Ideas

Moderna’s COVID-19 Vaccine Candidate Gets FDA Fast Track Status

Moderna Inc. (MRNA) announced on Tuesday that its experimental coronavirus vaccine has been granted fast track status by the U.S. Food and Drug Administration (FDA).The fast track status designation is awarded to speed up the regulatory review of its novel coronavirus vaccine candidate (mRNA-1273).Last week, the FDA completed its review of Moderna’s Investigational New Drug (IND) application for mRNA-1273 allowing it to proceed to a Phase 2 study, which is expected to begin shortly. The clinical stage biotech company said it is finalizing the protocol for a Phase 3 study, expected to begin in early summer of 2020.“Fast Track designation …read more […]

No Picture
Trading Ideas

Novavax Stock Soaring Due to Coronavirus Vaccine Candidate

Novavax stock is one of the biggest movers in the market right now. The Maryland-based vaccine company announced a massive investment that may be a saving grace in the fight against the coronavirus.

Why is Novavax Stock on the Rise?
Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage vaccine company with facilities in Maryland and Sweden. Like most biotech companies, it has joined in the fight against COVID-19.
However, it’s quickly making strides towards a vaccination candidate that has caught the eyes of investors. The Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to an additional $384 million to advance the potential vaccine’s …read more […]

No Picture
Trading Ideas

Investors Are Dumping Stocks for Bonds as Fed Buying Begins

(Bloomberg) — The Federal Reserve’s dive into corporate debt on Tuesday aligns the U.S. central bank with money managers around the world pivoting toward America Inc.’s bonds and away from its shares.Exchange-traded funds investing in credit saw $2.4 billions of inflows in the past week, compared to outflows for equities, data compiled by Bloomberg show.Funds targeting American stocks posted $9.3 billion of outflows in the period ending May 6, the most in six weeks, according to a Bank of America note citing EPFR Global data. The six-week inflow for high-yield bonds hit a record $32 billion.It’s the “follow the Fed” …read more […]

No Picture
Trading Ideas

3 Biotech Stocks Under $3 With 200%-Plus Upside Potential

The healthcare sector took its place among the winners this year, rising 11%, compared to the S&P 500’s 9% drop. The bottom-line for investors? Wall Street’s focus is on the healthcare space, locking in on biotechs in particular. However, before making hasty decisions, it should be noted that these stocks are notoriously risky, with their shares prone to explosive movements on account of only a few key catalysts like updates on clinical studies or regulatory approvals. The good news is that a favorable outcome can drive massive share price appreciation. However, the bad news is that the opposite holds true.Understanding …read more […]